Mycoplasma contamination revisited: Mesenchymal stromal cells harboring Mycoplasma hyorhinis potently inhibit lymphocyte proliferation In vitro

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Zinöcker, Severin ^a   Wang, Meng Yu ^b   Gaustad, Peter ^a   Kvalheim, Gunnar ^b   Rolstad, Bent ^a   Vaage, John T ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

THYMIDINE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM CONTAMINATION; BONE MARROW CELL; CELL ASSAY; CELL FUNCTION; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HOST PATHOGEN INTERACTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYME CELL; MICROBIAL ACTIVITY; MIXED LYMPHOCYTE REACTION; MYCOPLASMA HYORHINIS; MYCOPLASMOSIS; NONHUMAN; PROTEIN DEGRADATION; RAT; STROMA CELL; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CULTURE TECHNIQUE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL; MICROBIOLOGY; PATHOGENICITY; STANDARD;

ANIMALIA; MYCOPLASMA; MYCOPLASMA HYORHINIS; MYCOPLASMATALES; RATTUS;

ANIMALS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELLS; MYCOPLASMA HYORHINIS; RATS;

EID: 79251548540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016005     Document Type: Article

References (49)

1. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, et al. (2005) Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-395.
2. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
3. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV (1974) Stromal Cells Responsible for Transferring the Microenvironment of the Hemopoietic Tissues: Cloning In Vitro and Retransplantation In Vivo. Transplantation 17: 331-340.
4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science 284: 143-147.
5. da Silva Meirelles L, Chagastelles PC, Nardi NB (2006) Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119: 2204-2213.
6. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, et al. (2001) Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies. Tissue Eng 7: 211-228.
7. Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, et al. (2007) Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res 327: 449-462. doi:10.1007/s00441-006-0308-z.
8. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, et al. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30: 42-48.
9. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75: 389-397.
10. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, et al. (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigenspecific T cells to their cognate peptide. Blood 101: 3722-3729.
11. Le Blanc K, Tammik L, Sundberg B, Haynesworth S, Ringdén O (2003) Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex. Scand J Immunol 57: 11-20.
12. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, et al. (2004) Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 33: 597-604.
13. Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110: 3499-3506.
14. Nasef A, Ashammakhi N, Fouillard L (2008) Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med 3: 531-546.
15. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, et al. (2005) Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients. Biol Blood Marrow Transplant 11: 389-398.
16. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, et al. (2006) Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease. Transplantation 81: 1390-1397.
17. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, et al. (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579-1586. doi:10.1016/s0140-6736(08)60690-x.
18. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, et al. (2006) Adipose Tissue-Derived Mesenchymal Stem Cells Have In Vivo Immunosuppressive Properties Applicable for the Control of the Graft-Versus-Host Disease. Stem Cells 24: 2582-2591.
19. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F (2007) Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graftversus- host disease. Leukemia 21: 1992-1999.
20. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, et al. (2006) Bone Marrow Mesenchymal Stem Cells Suppress Lymphocyte Proliferation In Vitro but Fail to Prevent Graft-versus-Host Disease in Mice. J Immunol 176: 7761-7767.
21. Prigozhina TB, Khitrin S, Elkin G, Eizik O, Morecki S, et al. (2008) Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol 36: 1370-1376. doi:10.1016/j.exphem.2008.04.022.
22. Mielcarek M, Storb R, Georges GE, Golubev L, Nikitine A, et al. (2010) Mesenchymal Stromal Cells Fail to Prevent Acute Graft-versus-Host Disease and Graft Rejection after Dog-Leukocyte-Antigen Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant. In Press. doi:10.1016/j.bbmt.2010.08.015.
23. Nicholas RAJ, Ayling RD, McAuliffe L (2002) Vaccines for Mycoplasma Diseases in Animals and Man. J Comp Pathol 140: 85-96. doi:10.1016/j.jcpa.2008.08.004.
24. Drexler H, Uphoff C (2002) Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology 39: 75-90. doi:10.1023/A: 1022913015916.
25. Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, et al. (2009) Persistent Exposure to Mycoplasma Induces Malignant Transformation of Human Prostate Cells. PLoS ONE 4: e6872. doi:10.1371/journal.pone.0006872.
26. Sinigaglia F, Talmadge KW (1985) Inhibition of [3H]thymidine incorporation by Mycoplasma arginini-infected cells due to enzymatic cleavage of the nucleoside Eur J Immunol 15: 692-696.doi:10.1002/eji.1830150710.
27. Lyons AB (2000) Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 243: 147-154. doi:10.1016/S0022-1759(00)00231-3.
28. Horwitz E, Dominici M (2008) How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy 10: 771-774.
29. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822.
30. Rasmusson I, Uhlin M, Le Blanc K, Levitsky V (2007) Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 82:887-893.
31. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, et al. (2008) Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide. Cell Stem Cell 2: 141-150.
32. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, et al. (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce Tcell unresponsiveness. Blood 105: 2214-2219.
33. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte JJ, et al. (1996) An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88: 3230-3239.
34. Merkenschlager M, Kardamakis D, Rawle FC, Spurr N, Beverley PC (1988) Rate of incorporation of radiolabelled nucleosides does not necessarily reflect the metabolic state of cells in culture: effects of latent mycoplasma contamination. Immunology 63: 125-131. doi:10.1023/A:1022913015916.
35. Pollack JD, Tryon VV, Beaman KD (1983) The metabolic pathways of Acholeplasma and Mycoplasma: an overview. Yale J Biol Med 56: 709-716.
36. Sinigaglia F, Scheidegger D, Talmadge K, Garotta G (1985) A sensitive and quantitative microassay for the detection of mycoplasma contamination: inhibition of IL-2 dependent cell line proliferation. J Immunol Methods 76: 85-92.
37. Shahzad W, Ajuwape ATP, Rosenbusch RF (2010) Global suppression of mitogen-activated ovine peripheral blood mononuclear cells by surface protein activity from Mycoplasma ovipneumoniae. Vet Immunol Immunopathol 136: 116-121. doi:10.1016/j.vetimm.2010.02.001.
38. Bush TJV, Rosenbusch RF (2004) Characterization of a lympho-inhibitory peptide produced by Mycoplasma bovis. Biochem Biophys Res Commun 315: 336-341. doi:10.1016/j.bbrc.2004.01.063.
39. Totte P, Rodrigues V, Yaya A, Hamadou B, Cisse O, et al. (2008) Analysis of cellular responses to Mycoplasma mycoides subsp. mycoides small colony biotype associated with control of contagious bovine pleuropneumonia. Vet Res 39: 8. doi:10.1051/vetres: 2007046.
40. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EGA, Willemze R, et al. (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108: 2114-2120.
41. Jarvinen L, Badri L, Wettlaufer S, Ohtsuka T, Standiford TJ, et al. (2008) Lung Resident Mesenchymal Stem Cells Isolated from Human Lung Allografts Inhibit T Cell Proliferation via a Soluble Mediator. J Immunol 181: 4389-4396.
42. Badillo AT, Peranteau WH, Heaton TE, Quinn C, Flake AW (2008) Murine bone marrow derived stromal progenitor cells fail to prevent or treat acute graftversus- host disease. Br J Haematol 141: 224-234.
43. Siegel G, Schäfer R, Dazzi F (2009) The immunosuppressive properties of mesenchymal stem cells. Transplantation 87: S45-S49.
44. Kostyal DA, Butler GH, Beezhold DH (1995) Mycoplasma hyorhinis molecules that induce tumor necrosis factor alpha secretion by human monocytes. Infect Immun 63: 3858-3863.
45. Kagemann G, Henrich B, Kuhn M, Kleinert H, Schnorr O (2005) Impact of Mycoplasma hyorhinis infection on L-arginine metabolism: differential regulation of the human and murine iNOS gene. Biol Chem 386: 1055-1063. doi:10.1515/BC.2005.121.
46. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, et al. (2002) Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 36: 20-42.
47. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, et al. (2005) Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 205: 228-236.
48. Rosner C, Kruse P, Lübke T, Walter L (2010) Rhesus macaque MHC class I molecules show differential subcellular localizations. Immunogenetics 62: 149-158. doi:10.1007/s00251-010-0424-5.
49. Nestvold JM, Omdal BK, Dai KZ, Martens A, Benestad HB, et al. (2008) A Second Prophylactic MHC-Mismatched Bone Marrow Transplantation Protects Against Rat Acute Myeloid Leukemia (BNML) Without Lethal Graft-Versus- Host Disease. Transplantation 85: 102-111.